Given the task definition and input, reply with output. Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: Evolocumab met the main goal of a late-stage trial titled RUTHERFORD-2 by lowering "bad" LDL cholesterol levels when tested against a placebo on 329 patients. Amgen, the world's biggest biotechnology company, is testing evolocumab widely on a variety of subpopulations. The RUTHERFORD-2 study included patients with familial hypercholesterolemia, an inherited condition that causes high levels of "bad" LDL cholesterol starting at birth. Specifically, patients in the study had heterozygous familial hypercholesterolemia, which is one of the most common genetic disorders affecting about one out of every 300 to 500 people worldwide, according to Amgen. The company on Tuesday reported positive results from a fourth late-stage study of evolocumab, for which it plans to begin seeking approvals this year. The drug is intended for people who cannot tolerate widely used statins, or who are unable to get their LDL levels low enough despite using high potency statins, such as AstraZeneca's Crestor. Amgen's shares closed at $120.89 on the Nasdaq on Thursday. Claim: Amgen's cholesterol fighter succeeds in fifth late-stage study.
Amgen Inc said its experimental drug from a promising new class of injectable medicines succeeded in treating patients with genetically high cholesterol levels, marking the fifth successful clinical study of the drug.